Torrent Pharma is enhancing its anti-diabetes portfolio by acquiring three brands from Boehringer Ingelheim, expected to finalize in March 2025. The brands—Cospiaq, Cospiaq Met, and Xilingio—contain Empagliflozin, a key treatment for type 2 diabetes, in a market projected to grow at a 25% CAGR. This move aims to improve patient access to diabetes care in India, which is anticipated to have 12.5 crore diabetes patients by 2045.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
